Unexpected Individual Clinical Site Variation in Eradication Rates of Group A Streptococci by Penicillin in Multisite Clinical Trials
Authors:
- Edward L. KaplanEKEdward L. Kaplan
- J Michael OakesJOJ Michael Oakes
- Dwight R. JohnsonDJDwight R. Johnson
- 1 December 2007
- journal article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 26 (12) , 1110-1116
Abstract
Previously, we reported an unexpectedly large percentage of failures by penicillin to eradicate group A streptococci (GAS) from the upper respiratory tract. Because penicillin has been the recommended therapy for the treatment of GAS pharyngitis, our report prompted controversy. Data from clinical trials in which our laboratory has participated demonstrated marked variation in GAS eradication rates among clinical sites. The reasons for such variation have never been adequately examined. We performed statistical analyses of site variation in eradication rates to assess the potential effect on reported reduced penicillin efficacy. Penicillin GAS eradication rates were compared using data from 4 large multisite pharyngitis treatment trials (75 clinical sites; 1158 subjects). Variation in eradication rates among clinical sites was statistically evaluated [chi(2) tests and generalized estimating equation (GEE) regression models]. There was significant site-to-site variation in GAS eradication rates in each of the trials (range, 17-100%; P < 0.005) as well as between separate trials (mean range, 58-69%; P < 0.033). GEE modeling indicated that GAS eradication rates were significantly higher for clinical sites participating in more than one clinical trial. The statistically significant site-to-site variation in penicillin eradication rates was related to factors (dependencies) at individual sites. Such factors may affect assessment of therapeutic efficacy and indicate a necessity for considering clinical site variation before reporting pooled efficacy data from multiple sites; combined data may result in misleading clinical implications. This is the first report documenting significant variation resulting from individual clinical site-related factors and offers a possible explanation for reduced penicillin eradication.Keywords
This publication has 12 references indexed in Scilit:
- Reduced Ability of Penicillin to Eradicate Ingested Group A Streptococci from Epithelial Cells: Clinical and Pathogenetic ImplicationsClinical Infectious Diseases, 2006
- Meta-analysis of Cephalosporins versus Penicillin for Treatment of Group A Streptococcal Tonsillopharyngitis in AdultsClinical Infectious Diseases, 2004
- So What’s Wrong With Penicillin for Strep Throat?Pediatrics, 2004
- Are Cephalosporins Superior to Penicillin for Treatment of Acute Streptococcal Pharyngitis?Clinical Infectious Diseases, 2004
- Meta-analysis of Cephalosporin Versus Penicillin Treatment of Group A Streptococcal Tonsillopharyngitis in ChildrenPediatrics, 2004
- Practice Guidelines for the Diagnosis and Management of Group A Streptococcal PharyngitisClinical Infectious Diseases, 2002
- Unexplained Reduced Microbiological Efficacy of Intramuscular Benzathine Penicillin G and of Oral Penicillin V in Eradication of Group A Streptococci From Children With Acute PharyngitisPediatrics, 2001
- Susceptibility of Group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997The Pediatric Infectious Disease Journal, 1999
- Studies of the continuing susceptibility of group A streptococcal strains to penicillin during eight decadesThe Pediatric Infectious Disease Journal, 1998
- Prophylaxis of acute rheumatic feverThe American Journal of Medicine, 1951